^
BIOMARKER:

BIRC5 overexpression

i
Other names: BIRC5, API4, EPR-1, survivin, Baculoviral IAP repeat containing 5
Entrez ID:
Related biomarkers:
1m
Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma. (PubMed, World J Gastroenterol)
Survivin shows upregulated expression (indicative of anti-apoptotic effects) in HCC. Thus, survivin-positive CTCs are promising as a predictor of HCC prognosis and metastasis, and their accurate measurement may be useful for the management of this cancer.
Journal • Circulating Tumor Cells
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
1m
The abnormal expression of chromosomal region maintenance 1 (CRM1)-survivin axis in ovarian cancer and its related mechanisms regulating proliferation and apoptosis of ovarian cancer cells. (PubMed, Bioengineered)
The results of the rescue experiment showed that overexpression of survivin reversed the inhibitory effect of CRM1 knockdown on the proliferation of ovarian cancer cells and its inhibitory effect on apoptosis. Our findings confirm the role of the CRM1-survivin signal transduction axis in OC by regulating the proliferation and apoptosis of OC cells, and may thus serve as a potential therapeutic target for OC.
Clinical • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3)
|
BIRC5 overexpression
2ms
Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer. (PubMed, Front Oncol)
In addition, overexpression of BIRC5 protein was detected in afatinib-resistant cells by western blot, while BIRC5-expressing cells treated with BIRC5 inhibitor, YM155, were sensitive to afatinib. In this study, we showed that overexpression of BIRC5 resulted in resistance to afatinib in NSCLC and BIRC5-specific inhibitors may overcome the resistant phenotype, indicating that dysregulation of the apoptotic cell death pathway may be the key mechanism underlying TKI resistance in the development of NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
|
Gilotrif (afatinib) • sepantronium bromide (YM155)
3ms
Expression of survivin in oral leukoplakia and oral lichen planus. (PubMed, Minerva Dent Oral Sci)
Expression of survivin in potentially malignant lesions indicate potential risk of malignant transformation.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
4ms
LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5. (PubMed, Mol Biotechnol)
In vivo, LINC00511 knockdown attenuated the tumorigenesis of A549/DDP cells after DDP injection. These results provide a novel LINC00511/miR-182/BIRC5 paradigm to explain the mechanism of acquired DDP resistance.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • MIR182 (MicroRNA 182)
|
BIRC5 overexpression
|
cisplatin
6ms
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold. (PubMed, Eur J Med Chem)
Further evaluation using an aggressive, orthotopic ovarian cancer mouse model showed that 12b was highly efficacious in suppressing both primary tumor growth in ovaries and tumor metastasis to multiple peritoneal organs. Collectively, results in this study strongly suggest that the hydroxyquinoline scaffold, represented by 12b and our earlier lead compound MX-106, has abilities to selectively target survivin and is promising for further preclinical development.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
6ms
DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5. (PubMed, Cell Death Dis)
Moreover, BIRC5 overexpression reduced the inhibitory effects of DEPDC1B knockdown in chordoma cells. In conclusion, DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5, suggesting that it may be a promising candidate target with potential therapeutic value.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
8ms
Prognostic significance of survivin expression in pediatric ewing sarcoma. (PubMed, Pediatr Hematol Oncol)
It was confirmed as an independent factor in multivariate analysis for OS (p: 0.041; HR: 1.97 with 95% CI of 1.03-3.79) and EFS (p: 0.049; HR: 1.86 with 95% CI of 1.00-3.46). These results suggest that high survivin expression identifies a group of patients with poor prognosis and this may help to refine risk adapted treatment; however, this needs to be confirmed in prospective studies.
Clinical • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
9ms
New trial
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
10ms
Mutant p53 regulates Survivin to foster lung metastasis. (PubMed, Genes Dev)
Furthermore, Survivin high expression level is associated with increased metastasis in several GI cancers. Taken together, this study unravels new insights into how mutant p53 mediates metastasis.
Journal
|
TP53 (Tumor protein P53) • BIRC5 (Baculoviral IAP repeat containing 5)
|
TP53 mutation • BIRC5 expression • BIRC5 overexpression
11ms
Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. (PubMed, Exp Ther Med)
The diagnostic performance of Survivin-1, Tag-72 and HERC5 tissue biomarkers for HCC characterization was superior to that of the gold-standard AFP. Our study results validate the overexpression of Survivin-1, Tag-72, and HERC5 as tissue biomarkers for HCC characterization in patients from our geographical region and could be standardized in the current HCC management guideline.
Clinical • Journal
|
MDM2 (E3 ubiquitin protein ligase) • BIRC5 (Baculoviral IAP repeat containing 5) • ALB (Albumin)
|
BIRC5 overexpression
1year
Survivin Regulates Bad Gene Expression by Binding to Its Promoter and Modulates Cell Cycle and Apoptosis in Esophageal Carcinoma Cell. (PubMed, J Oncol)
ChIP assays indicate that survivin directly binds to the Bad promoter region, diminishing the transcriptional activity of Bad. In conclusion, the result suggested that survivin regulates Bad gene expression by binding to its promoter and modulates cell cycle and apoptosis in esophageal carcinoma cell.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
1year
LncRNA NLIPMT Inhibits Tumorigenesis in Esophageal Squamous-Cell Carcinomas by Regulating miR-320/Survivin Axis. (PubMed, Cancer Manag Res)
We demonstrate that NLIPMT inhibits cell proliferation and migration and promotes cell cycle arrest and apoptosis in ESCC cells by regulating the miR-320/survivin axis. NLIPMT may be a novel prognosis biomarker in ESCC patients.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
1year
Discovery of Novel 3-Cyanopyridines as Survivin Modulators and Apoptosis Inducers. (PubMed, Molecules)
In addition, their activities were evaluated in comparison with a standard anticancer drug 5-FU...The results revealed a striking reduction in survivin expression through proteasome-dependent survivin degradation in addition to a decrease in the expression of some other inhibitor of apoptosis proteins (IAP) family proteins: Livin, XIAP, and C-IAP1 in a concentration-dependent manner. A docking study of 5c and 5e compounds in the dimerization site of survivin was also performed, showing agreement with the in vitro anti-survivin activity.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
|
fluorouracil topical
1year
Curcusone C induces apoptosis in endometrial cancer cells via mitochondria-dependent apoptotic and ERK pathway. (PubMed, Biotechnol Lett)
Taken together, the results demonstrate the anti-endometrial cancer potential of Curcusone C for the treatment of endometrial cancer.
Journal
|
BCL2L1 (BCL2-like 1) • BCL2L11 (BCL2 Like 11) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BIRC5 expression • BAX expression • BIRC5 overexpression
|
U0126
over1year
lincRNA-RP11400K9.4 Regulates Cell Survival and Migration of Breast Cancer Cells. (PubMed, Cancer Genomics Proteomics)
RP11-400K9.4 participates in the modulation of migration and survival processes probably via the BIRC3/NFĸB pathway.
Journal
|
BIRC3 (Baculoviral IAP repeat containing 3)
|
BIRC5 overexpression
over1year
[VIRTUAL] Role of the transcription factor YY1 in B-cell non-Hodgkin lymphoma development (SOHO Italy 2020)
Abstract Introduction Yin Yang 1 (YY1) is a transcription factor with a dual role in cancer B-cell non-Hodgkin lymphomas (B-NHLs) are often characterized by the development of recurrence and/or resistance to therapy The aim of this study was to investigate the pro-tumorigenic function of YY1 in reversing drug-resistance, as well as to identify YY1 downstream resistant factors in B-NHLs Methods Predictive studies coupled with analyses of deposited-Chip-Sequencing, as well as Gene Expression Omnibus (GEO) B-NHL repositories, were used to: (1) Identify YY1 transcriptional target(s) which may regulate the apoptosis; (2) Assess the diagnostic role of YY1 and the identified target(s) The in-silico studies were subsequently validated in vitro by using a model of aggressive Burkitt’s Lymphoma (BL), the Raji cell line Results The bioinformatics analyses suggested that: (1) YY1 bound the promoter of the BIRC5/survivin anti-apoptotic gene; (2) Both YY1 and survivin were highly expressed in B-NHLs, especially in aggressive ones; (3) There was a conserved positive correlation between YY1 and survivin in all the B-NHL GEO datasets analyzed Validation experiments performed in Raji cells further demonstrated that YY1 silencing: (1) was associated with survivin downregulation; (2) sensitized the cells to apoptosis Conclusions Overall, our results revealed that: (1) Survivin could be proposed as YY1 transcriptional target; (2) YY1 and survivin are positively correlated and both found overexpressed in B-NHLs, especially in BLs; (3) YY1 knockdown sensitizes Raji cells to drug-induced apoptosis via downregulation of survivin; (4) both YY1 and survivin might be suggested as potential diagnostic biomarkers and therapeutic targets for the treatment of resistant/recurrent B-NHLs
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
over1year
PKM2-c-Myc-Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer. (PubMed, Front Pharmacol)
In addition, the elevated level of PKM2 correlates with poor relapse-free survival in breast cancer patients treated with tamoxifen. Overall, our findings demonstrated that PKM2-c-Myc-survivin cascade regulated the proliferation, migration and tamoxifen resistance of breast cancer cells, suggesting that PKM2 represents a novel prognostic marker and an attractive target for breast cancer therapeutics, and that PKM2 inhibitor combined with tamoxifen may be a promising strategy to reverse tamoxifen resistance in breast cancer patients.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BIRC5 (Baculoviral IAP repeat containing 5)
|
MYC expression • BIRC5 expression • BIRC5 overexpression
|
tamoxifen
over1year
Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. (PubMed, Int J Mol Sci)
Further validation experiments performed in Raji Burkitt's lymphomas cells, demonstrated that YY1 silencing was associated with survivin downregulation and sensitized the cells to apoptosis. Overall, our results revealed that: (1) YY1 and survivin are positively correlated and overexpressed in B-NHLs, especially in BLs; (2) YY1 strongly binds to the survivin promoter, hence survivin may be suggested as YY1 transcriptional target; (3) YY1 silencing sensitizes Raji cells to drug-induced apoptosis via downregulation of survivin; (4) both YY1 and survivin are potential diagnostic markers and therapeutic targets for the treatment of resistant/relapsed B-NHLs.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
over1year
Upregulation of DR5 and Downregulation of Survivin by IITZ-01, Lysosomotropic Autophagy Inhibitor, Potentiates TRAIL-Mediated Apoptosis in Renal Cancer Cells via Ubiquitin-Proteasome Pathway. (PubMed, Cancers (Basel))
Moreover, IITZ-01 decreased expression level of survivin protein via downregulation of deubiquitinase ubiquitin-specific protease 9X (USP9X) expression. Taken together, these results provide the first evidence that IITZ-01 enhances TRAIL-mediated apoptosis through DR5 stabilization by downregulation of Cbl and USP9X-dependent survivin ubiquitination and degradation in renal carcinoma cells.
Journal
|
CBL (Cbl proto-oncogene) • TNFA (Tumor Necrosis Factor-Alpha) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
over1year
Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy. (PubMed, Clin Epigenetics)
Since Survivin can be secreted and we observed a high abundance of the protein also in the adjacent immune cells of the tumor microenvironment, an effect on benign cells can be assumed. These findings show that epigenetic re-programming of Survivin and Regucalcin in non-small cell lung cancer leads to enhanced expression of Survivin and reduced expression of Regucalcin, with a possible role of both molecules as predictive markers.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
over1year
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • CDK1 (Cyclin-dependent kinase 1)
|
BIRC5 overexpression
over1year
[VIRTUAL] Identification of novel BIRC5/survivin splice variants in cancer (AACR-II 2020)
We have identified multiple novel splice variants of survivin, including Δex3/2B, 4B, and Δex3/4B. Proteins encoded by these transcripts potentially have pro- or anti-oncogenic functions, and further studies are needed to delineate their role in survivin biologies.
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
over1year
Evaluation and Expression of Survivin in Potentially Malignant Lesions and Squamous Cell Carcinoma: A Comparative Study. (PubMed, Cureus)
The prognosis of oral squamous cell carcinomas becomes poorer with increased expression of survivin. Therefore, survivin might be helpful as an important therapeutic target because it is expressed more in tumor cells and absent in most adult tissues.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
almost2years
Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt. (PubMed, Clin Breast Cancer)
Genetic variation in -31G/C of the survivin gene may contribute to the disposition of breast cancer in the Egyptian population. Serum survivin alteration played a pivotal role in the pathogenesis of breast cancer.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
almost2years
Basal-Type Breast Cancer Stem Cells Over-Express Chromosomal Passenger Complex Proteins. (PubMed, Cells)
Analysis of previously published cohorts showed that this co-regulated module was not only overexpressed in basal breast tumors but also associated with relapse-free and overall survival in these patients. (4) These results underline the importance of Cancer Stem Cells in breast cancer progression and point toward the possible use of chromosomal passenger proteins as prognostic factors.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
almost2years
Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving. (PubMed, Cancer Res Treat)
In addition, miR-454 inhibitor or overexpression of survivin was found to abolish sh-CCAT1-induced apoptosis upon cisplatin treatment. CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
|
cisplatin
almost2years
LncRNA HCP5 Stimulates the Proliferation of Non-Small Cell Lung Cancer Cells by Up-Regulating Survivin Through the Down-Regulation of miR-320. (PubMed, Cancer Manag Res)
In addition, miR-320 overexpression reduced the effects of HCP5 overexpression. Therefore, HCP5 may stimulate the proliferation of NSCLC cells by up-regulating survivin through the down-regulation of miR-320.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
almost2years
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications. (PubMed, Blood Rev)
Moreover, we highlight the relevance of molecular networks involving survivin for disease progression and treatment resistance. Finally, we discuss the mechanisms accounting for survivin overexpression, as well as novel therapeutic interventions that have been designed to counteract survivin-associated malignancy in CML.
Clinical • Review • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression
almost2years
Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. (PubMed, BMC Cancer)
Our study demonstrates that BMSC-induced resistance to drugs is associated with survivin upregulation which is a direct target of miR-101-3p. This study also identifies miR-101-3p-survivin interaction as a druggable target involved in stroma-mediated drug resistance in MM and suggests it for developing more efficient therapeutic strategies.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 overexpression